Goldman Sachs maintains Kenvue stock rating amid potential Tylenol report

Kenvue (KVUE) faces significant headline risk from an anticipated HHS report potentially linking prenatal Tylenol use to autism, a development that could impact the brand representing 8-9% of its global sales and lead to a 2-3% FY2026 EPS headwind for every 2% sales decline. Despite a previous court ruling finding insufficient evidence for a similar claim, this uncertainty has generated mixed analyst reactions, with some maintaining positive ratings while others, like Goldman Sachs (Neutral) and Evercore ISI (target adjustment), express caution. The market remains focused on the report's official release, as its contents are not yet disclosed.

Analysis

Kenvue Inc. (KVUE) is currently navigating significant headline risk centered on its Tylenol brand, which accounts for an estimated 8-9% of its global sales. The market is anticipating a U.S. Department of Health and Human Services (HHS) report which media reports speculate may link prenatal acetaminophen use to autism, creating uncertainty that has contributed to a stock decline of over 10% in the past week and pushed it into technically oversold territory. Goldman Sachs quantifies the potential damage, estimating a 2-3% headwind to FY2026 EPS for every 2% of total company sales lost. This risk is counterbalanced by Kenvue's strong fundamentals, including impressive gross profit margins of 58.15% on $15.14 billion in annual revenue, and a favorable legal precedent from a December 2023 ruling that found a lack of admissible evidence for a similar claim, though that ruling remains under appeal. Analyst sentiment is sharply divided, reflecting the binary nature of the risk: Goldman Sachs and Evercore ISI remain cautious, with the latter cutting its price target to $23, while JPMorgan and Canaccord Genuity maintain Overweight/Buy ratings with price targets of $24 and $26 respectively, suggesting they view the legal risk as minimal based on current data.

Key Decisions for Investors

• Investors must weigh the significant, event-driven downside risk from the pending HHS report against the company's strong fundamental metrics, such as its 58.15% gross profit margin.
• The stock's recent 10% decline and oversold technical status may present a tactical entry point for investors with a higher risk tolerance who believe the Tylenol concerns are overstated, a view supported by bullish analysts at JPMorgan.
• Closely monitor the official findings of the HHS report and the outcome of the ongoing Second Circuit appeal, as these are the primary catalysts that will resolve the current uncertainty and dictate the stock's medium-term trajectory.